Aytu BioPharma Q4 FY26 net loss narrows to USD 15,000; revenue rises 6.4% to USD 16.1 million vs Q4 FY25
Bitget2026/09/22 20:06- Aytu Biopharma reported Q4 fiscal 2026 net revenue rose 6.4% to USD 16.1 million versus the year-ago quarter.
- Net loss narrowed to USD 15,000, versus USD 19.82 million a year earlier.
- Full-year net revenue fell 13.3% to USD 57.6 million, and net loss widened to USD 14.25 million.
- EXXUA produced USD 3.94 million of Q4 net revenue, its first full quarter of launch, and USD 6.57 million for the year.
- CEO Josh Disbrow said Q4 prescriptions topped 3,300, more than doubled sequentially, while June reached a record 1,261 scripts.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Honda Motor (HMC.US) Reports 65.7% Increase in Net Profit in the First Half, Plans to Expand Production Capacity in North America and Brazil
Honda Motor (HMC.US) released its financial results for the first half of fiscal year 2027 on November 10.
Crypto winter not over? Mining rig hosting provider Bitari cancels orders at the last minute, IPO plans put on hold
Bitcoin mining service provider Bitari has withdrawn its Nasdaq IPO plan. The company originally intended to issue 4.3 million shares at $7 per share to raise $30 million. Its annual revenue is approximately $11 million.
Pre-orders for GTA 6 are booming and may reverse the downward trend! Citigroup raises Take-Two Interactive Software (TTWO.US) target to $270
Citigroup maintains a "Buy" rating on Take-Two Interactive Software, with a target price of $270.
Crypto prices
More
